Predictive Oncology Inc. announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (GPCRs). GPCRs are cell surface membrane receptors that are believed to play a key role in tumorigenesis, with prior studies demonstrating involvement in cancer initiation, progression, and metastasis. It is estimated that drugs targeting GPCRs represent more than 30% of the global market for therapeutic drugs, yet the number of characterized GPCR targets represent just a small fraction of the GPCR superfamily, suggesting significant potential to further target GPCRs for future drug discovery and development.

Predictive Oncology plans to combine this proprietary GPCR expression system with its current High-Throughput Self-Interaction Chromatography (HSC??) protein solubilization technology to enable the rapid identification of solution conditions that maintain purified GPCRs in a soluble and stable form. The company believes this can overcome many of the difficulties seen with existing expression technologies.